Group items tagged

Water - Based Interventions for the Pediatric Therapies is organized by Texas Children's Hospital and will be held during Mar 03 - 04, 2018 at Blue Lagune Therapy - Aquatic & Land Physical Therapy, Katy, Texas, United States of America. This CME Conference has been approved for a maximum of 16 CCUs Credits. Course Description: This Course is designed to rapidly introduce pediatric therapists to motor, sensory and play-based interventions in water. Participants will create a series of aquatic therapeutic movements, tasks, or exercises designed to alleviate the most common problems associated with the pediatric population and then adapte these ideas to novel situations. Participants will briefly examine research which supports aquatic therapy for the child and explore contraindications, including prevailing precaution myths. Course Objectives : * Discriminate between aquatic precautions and contraindications specific to the pediatric client. Defend any choice, on a case-by-case basis, to label a condition as a precaution and not as a contraindication. * Explain why aquatic therapy may be the treatment of choice if (a) the patient has poor head or trunk righting/control, (b) the patient has spasticity, (c) the patient has difficulty with transitional movements; (d) the patient has poor sensory processing; (e) the patient has speech/language deficits; or (f) research supports its use. * Design a sample aquatic treatment session demonstrating 2 ways to divide labor between PT, OT and SLP. Compare and contrast 5 ways that the goals of 3 different disciplines should differ. Recommend 3 ways to co-treat in water and be reimbursed for the services provided. * Originate, integrate, and combine ideas into a plan to implement augmentative communication in the therapy pool setting. Incorporate low-tech augmentative communication methods during labs to improve communication. * Gather and organize the latest aquatic research to bolster the case for treatment and to aid in t

Diabetes Intensive Training is organized by Mayo clinic and would be held during Jul 10 - Sep 29, 2017. The target audience for this medical event basically for Endocrinology, Metabolism and Diabetes, The CME conference has been approved with maximum of 32.00 AMA PRA Category 1 Credit. he Diabetes Intensive Training online course is a comprehensive web based graduate credit level professional enhancement course geared toward practicing professionals. Diabetes Intensive Training is an online self-paced 12 week course through Blackboard Learn. The course is offered on a quarterly basis. The curriculum includes a pretest, 16 modules for study, a post-test requiring an 80% passing score for continuing education credit, and a required evaluation of the course at completion. Currently the curriculum is offered to physicians, physician assistants, advanced nurse practitioners, registered nurses and pharmacists with a current license without restrictions. Target audience: This course is designed for Primary care providers - Family Medicine and General Internal Medicine MDs, Pharmacists, Dietitians, NPs, RNs and APRNs. Learning objectives: Upon conclusion of this program, participants should be able to: * Integrate the principles of theory and research of nursing and medicine into comprehensive health care plan for patients with diabetes including prevention, promotion and treatment * Demonstrate knowledge of evidence based and clinical guidelines in treatment of diabetes inpatient and outpatient management. * Develop and acquire skills for self- directed lifelong learning and staying current in diabetes management (prevention, promotion and treatment).

eMedEvents is recognized as a Winner of eHealthcare Leadership Awards at a special presentation on November 11, 2015 at the 19th Annual Healthcare Internet Conference in Orlando, Florida. eMedEvents won the Best Overall Internet Site-Silver award under physician focused category for an outstanding website. Judges reviewed eMedEvents based on a proprietary multi-point standard of Internet excellence. The Best Overall Internet Site category had to meet more than 40 factors. Ms. Priya Korrapati, CEO of eMedEvents, has said, "We passionately believe in building a technology empowered platform that helps healthcare professionals and provide tools to find medical conferences that fits each physician's unique CME needs" on winning the prestigious award. The eHealthcare Leadership Awards 2015 has received tremendous response with over 1000 entries competing in 15 different categories and diverse healthcare backgrounds. The awards highlight the role played by the Internet in helping healthcare organizations achieve their objectives. The awards also celebrate the hard work that lies underneath each of the winning websites and digital communications initiatives. About eMedEvents eMedEvents is a leading website with most comprehensive database of medical conferences for physicians to discover medical conferences that fit with their unique needs such as CME credits, Location preferences and Board reviews. With over 6000 medical conferences 2015 to choose from, the website is a perfect location to find any medical conference in multiple medical specialties across the globe. About eHealthcare Leadership awards The Healthcare Internet Conference is a popular event that brings together the leaders from various disciplines of the healthcare industry to learn, collaborate and celebrate best practices. The conference aims at helping the healthcare leaders with the ever growing challenges of the online world through collaboration with leading marketers, and other web based service

Vascular Interventional Advances Annual Conference (VIVA) is organized by Vascular Interventional Advances (VIVA) and would be held during Nov 11 - 15, 2017 at Wynn Las Vegas, Las Vegas, Nevada, United States of America. TARGET AUDIENCE : The target audience for this CME activity is physicians who specialize in, among other areas, interventional cardiology, interventional radiology, vascular medicine, vascular surgery, cardiothoracic surgery, neurosurgery, podiatry and neuroradiology, as well as fellows, and allied health professionals (including nurses, vascular clinic staff, endovascular operating room staff, catheterization laboratory and angiography suite staff, nurse practitioners, vascular technologists, and physicians assistants). LEARNING OBJECTIVES : At the conclusion of the course, the targeted learners should be able: * Understand the current indications, risks, complications, and outcome of medical, interventional, and surgical therapies for the treatment of peripheral arterial and venous diseases. * Incorporate advanced medical, endovascular, and surgical techniques and approaches into their own practices to improve the care and outcomes of patients. * Implement high quality guidelines based programs to improve the early identification and care of patients with non- cardiac vascular conditions. * Increase knowledge in critical decision-making and the comprehensive spectrum of care for patients with stroke and intracranial and extracranial carotid artery disease. * Improve the delivery of balanced and scientifically valid vascular care in accordance with expert opinion and practice. * Utilize strategies learned from the meeting including endovascular technologies, open surgical techniques, and hybrid approaches, for the treatment of patients with aortic diseases. * To gain and employ decision making and procedural strategies and techniques in patients with aortic and visceral aneurysms, dissections, deep venous thrombosis, venous insufficiency and pu

Torticollis and Plagiocephaly: Assessment and Treatment of Infants and Children is organized by Texas Children's Hospital and will be held during Mar 16 - 18, 2018, Houston, Texas, USA. The target audience for this medical event is Physical, Occupational & Speech Therapists; Nurses, including NICU, Nurse Practitioners, Orthotists, Physician Assistants, and Physicians. This CME Conference has been approved for a maximum of 13.5 contact hours or 1.35 CEU's Credits. Course Description: This dynamic evolving course will concentrate on progressive, effective treatment schemes for infants and young children with a diagnosis of torticollis with or without plagiocephaly, including challenging cases. The course is designed to provide therapists with current research and recommendations pertaining to the implications of torticollis, sleep posture and increased use of positional devices on infant postural and motor development. Current evidence-based clinical pathways and guidelines for management of torticollis and infant head shape, including Clinical Practice Guidelines from APTA - Section on Pediatrics, will be discussed and incorporated. Red flags for related early infancy and preschool diagnoses will be appraised. Current functional, clinically oriented evaluation and evidence based treatment strategies for infants and young children that can be integrated into routines and play will be provided. Diagnostic procedures and surgical intervention will be reviewed. Recommendations for follow-up and secondary specialist consultations will be presented. Emphasis on home exercise programs and effective strategies to team with parents will be explored.

A novel bioinformatics approach can predict vaccine effectiveness for the influenza season, and indicates that the current vaccines are likely to be effective against H3N2 flu viruses in the U.S. 2017/2018 flu season, according to research published online Nov. 29 in F1000 Research. Slobodan Paessler, D.V.M., Ph.D., from the University of Texas Medical Branch, and Veljko Veljkovic, Ph.D., from Biomed Protection, both in Galveston, Texas, used a bioinformatics platform to predict vaccine effectiveness for the 2017/2018 influenza season in the United States. The hemagglutinin HA1 region of 251 and 113 human H3N2 viruses collected in Australia and the United States from July to September 2017 were analyzed. The informational spectrum method-based phylogenetic analysis of H3N2 viruses was performed to serve as a base for predicting vaccine effectiveness. The researchers found that analyses of Australian viruses generated two clusters; the vaccine virus was placed in the smaller group. As a result, the vaccine was predicted not to be efficient against most Australian H3N2 viruses in the 2017 flu season; low vaccine effectiveness was reported in Australia in the 2017 flu season in accordance with this prediction. The U.S. H3N2 viruses were also grouped into two clusters, but the vaccine virus was placed in the largest cluster encompassing 71 percent of analyzed viruses. Consequently, the vaccine effectiveness is expected not to be suboptimal in the United States.

Mayo Clinic Hospital Medicine: Managing Complex Patients is organized by Mayo Clinic and would be held during Nov 08 - 11, 2017 at Loews Ventana Canyon Resort, Tucson, Arizona, United States Of America. The target audience for this medical event for inpatient care providers including physicians, nurse practitioners and physician assistants. Hospitalists are defined as those who spend most of their professional practice caring for hospitalized patients. This CME Conference has been approved with a maximum of 25.25 AMA PRA Category 1 Credits. Hospital Medicine is the fastest growing medical specialty and requires a diverse skill set. Hospital-based health care providers must be able to diagnose and manage a wide variety of clinical conditions, coordinate transitions of care, provide perioperative management to surgical patients and contribute to quality improvement and hospital administration. This program is specifically designed to ensure that participants augment their skill set to meet these many challenges in an effort to enhance the delivery of health care and provide better patient outcomes. Using an interactive, case-based format, key highlights from most major areas of hospital medicine will be presented. Conference Objectives are : * Classify a patient presenting with MI according to the most recent guidelines. * Select the appropriate indications for troponin testing. * Manage a patient with subsegmental pulmonary embolism. * Define sepsis according to the most recent clinical guidelines. * Select the appropriate antibiotics for a hospitalized patient with health-care associated pneumonia. * List strategies to improve the mobility of elderly patients in the hospital. * Manage a patient admitted to the hospital with diabetic ketoacidosis. * Recognize common sources of cognitive bias and heuristics to minimize their impact on patient care. * Order the appropriate tests for a hospitalized patient with a newly-diagnosed pleural effusion. * List novel the

Management of type 2 diabetes should include shared decision making, and patients should be offered individualized diabetes self-management education and glycemic management plans, according to a summary of a clinical practice guideline published online Oct. 23 in the Annals of Internal Medicine. Paul R. Conlin, M.D., from the VA Boston Healthcare System in West Roxbury, Massachusetts, and colleagues convened a joint U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) Evidence-Based Practice Work Group to develop a guideline for management of type 2 diabetes mellitus. The authors provided updates on management within seven areas: patient-centered care and shared decision making, glycemic biomarkers, target ranges of hemoglobin A1c (HbA1c), individualized treatment plans, pharmacologic treatment in the outpatient setting, glucose targets for critically ill patients, and treatment for patients in the hospital. Patients should be offered individualized diabetes self-management education, as well as individualized glycemic management plans and target ranges for HbA1c. "In summary, the VA/DoD CPG [clinical practice guideline] attempts to convey to clinicians, policymakers, and patients the rationale for personalizing treatment on the basis of results from major trials, limitations of the HbA1c test, and evaluation of patient risk for adverse drug events. Conveying complex information in an understandable manner to individual patients and families through a formal process of shared decision making is thus foundational to setting and revising goals that are meaningful, safe, and achievable in everyday clinical practice," the authors write.

For young patients with type 1 diabetes, insulin pump therapy is associated with lower risks of severe hypoglycemia and diabetic ketoacidosis and better glycemic control than insulin injection therapy, according to a study published online Oct. 10 in the Journal of the American Medical Association. Beate Karges, M.D., from RWTH Aachen University in Germany, and colleagues conducted a population-based cohort study in 446 diabetes centers. They identified patients with type 1 diabetes who were younger than 20 years and had diabetes duration of more than one year. The researchers found that 14,119 patients used pump therapy and 16,460 used insulin injections. A total of 9,814 patients using pump therapy were matched with 9,814 using injection therapy. Compared with injection therapy, pump therapy was correlated with lower rates of severe hypoglycemia (9.55 versus 13.97 per 100 patient-years) and diabetic ketoacidosis (3.64 versus 4.26 per 100 patient-years). Lower levels of glycated hemoglobin were seen with pump versus injection therapy (8.04 versus 8.22 percent). Compared with injection therapy, pump therapy was associated with lower total daily insulin doses (0.84 versus 0.98 U/kg). No significant difference in body mass index was seen between the treatment regimens

Transcatheter Cardiovascular Therapeutics (TCT) is organized by CardioVascular Research Foundation (CRF) and would be held during Oct 29 - Nov 2, 2017 at Colorado Convention Center, Denver, Colorado, United States of America. The target audience for this medical event for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine. Activity Goals : The overall goal of this activity is to improve the competence and performance of our target audience by delivering cutting-edge educational content that showcases the latest advances in current therapies and clinical research. We hope that our longstanding commitment to lifesaving innovation will translate into improved patient care. Learning Objectives : By the end of the symposium, participants should be able to: * Apply the results from important clinical trials and evidence-based medicine to guide the management of patients with atherosclerosis and structural heart disease * Incorporate new interventional technologies and procedures into the care of patients with complex coronary and endovascular disease * Integrate advances in diagnostic evaluation and therapeutics into the treatment of patients with carotid and peripheral arterial disease * Implement appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during, and after catheterization * Identify new interventional technologies and propose appropriate applications for patients with cardiovascular disease

eMedEvents offers free Online CME & CE Courses for physicians and health care professionals .Find CME online by browsing eMedEvents' database of text-based, webcast and journal CME and help you to earn CME points online .

Transcatheter Cardiovascular Therapeutics (TCT) is organized by CardioVascular Research Foundation (CRF) and would be held during Oct 29 - Nov 02, 2017 at Colorado Convention Center, Denver, Colorado, United States of America. The target audience for this medical event for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine. Activity Goals : The overall goal of this activity is to improve the competence and performance of our target audience by delivering cutting-edge educational content that showcases the latest advances in current therapies and clinical research. We hope that our longstanding commitment to lifesaving innovation will translate into improved patient care. Learning Objectives : By the end of the symposium, participants should be able to: * Apply the results from important clinical trials and evidence-based medicine to guide the management of patients with atherosclerosis and structural heart disease * Incorporate new interventional technologies and procedures into the care of patients with complex coronary and endovascular disease * Integrate advances in diagnostic evaluation and therapeutics into the treatment of patients with carotid and peripheral arterial disease * Implement appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during, and after catheterization * Identify new interventional technologies and propose appropriate applications for patients with cardiovascular disease

Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson's disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics. Bao-Dong Li, from the Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine in China, and colleagues conducted a systematic review to compare the adverse effects of 11 drugs used to treat Parkinson's disease. Data were included from 24 randomized controlled trials. The researchers found that, compared with placebo, the incidence of adverse reactions of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea. The incidence rates of dyskinesia side effects were highest with ropinirole, while in terms of patients' hallucination, pramipexole was significantly higher. The surface under the cumulative ranking curve values of all drugs showed that the incidence of adverse reaction of pergolide was relatively high (nausea, 83.5 percent; hallucination, 79.8 percent); the incidence of dyskinesia and somnolence was higher with ropinirole (80.5 and 69.4 percent); in terms of dizziness, the incidence of adverse reaction of piribedil was higher (67.0 percent), and in terms of constipation, the incidence of bromocriptine was relatively high (62.3 percent). "In addition to current forms of treatment, we hope that our results can produce useful information for further development of new drugs to treat Parkinson's disease based on the natures of each drug," the authors write.

Assessment of Motor and Process Skills (AMPS) Training Workshop is organized by Texas Children's Hospital and will be held during Mar 07 - 11, 2018 at Texas, USA. This CME Conference has been approved for a maximum of 38.75 contact hours. Course Description are : The Assessment of Motor and Process Skills (AMPS) is used to measure how well a client performs familiar activities of daily living (ADL). The AMPS can be used with any client, regardless of diagnosis or age, as long as the client is at least the developmental age of 2 years and is familiar with performing some ADL tasks. There are over 125 ADL tasks included in the AMPS, from very easy self-care tasks to multi-step domestic tasks (including outdoor tasks and shopping). The AMPS measures represent how well the client performs ADL tasks, in terms of physical effort, efficiency, safety, and independence. These measures take into consideration the difficulty of the tasks the client performed and the unique scoring severity of the occupational therapist administering the AMPS. The occupational therapist can use a client's AMPS measures to plan the occupation-based and occupation-focused intervention, develop occupation-focused goals, and write occupation-focused documentation. AMPS measures can also be used as outcome measures providing evidence that a client's occupational performance changed. Using this innovative assessment tool will expand your practice by helping you deliver more occupation-centered services. Course Objectives are : Upon successful completion of this course, participants will be able to: * Understand the theoretical foundation for using the assessment tool to promote occupation centered and client-centered practice. * Administer, score, and interpret the assessment tool in a valid and reliable manner. * Use assessment results to plan occupational therapy interventions. * Interpret the results of a follow-up assessment to analyze the effectiveness of interventions. * Integr

For patients with unruptured intracranial aneurysms (UIAs) that are 3 mm or smaller, no preventive treatment or imaging follow-up is the most effective management strategy, according to a study published online Nov. 20 in JAMA Neurology. Ajay Malhotra, M.D., from the Yale School of Medicine in New Haven, Conn., and colleagues used inputs from the medical literature to conduct a decision-analytic model-based comparative effectiveness analysis. Five management strategies were assessed: annual magnetic resonance angiography (MRA) screening, biennial MRA screening, MRA screening every five years, aneurysm coiling and follow-up, and no treatment or preventive follow-up. In an analysis of 10,000 iterations simulating adult patients, the researchers found that the highest health benefit was seen for the management strategy of no treatment or preventive follow-up (mean quality-adjusted life-years, 19.40). MRA every five years was the best of the management strategies that incorporate follow-up imaging, with the next highest effectiveness (mean quality-adjusted life-years, 18.05). When the annual growth rate and risk of rupture of growing aneurysms are varied, no routine follow-up remains the optimal strategy. No follow-up is the optimal strategy when the annual risk of rupture of nongrowing UIAs is less than 1.7 percent; coiling should be performed directly if the annual risk of rupture is >1.7 percent.

Intensive blood pressure lowering may similarly decrease cardiovascular events in both patients with and patients without type 2 diabetes mellitus, according to a study published online Dec. 6 in Diabetes Care. Tom F. Brouwer, M.D., from the University of Amsterdam, and colleagues assessed the effect of both type 2 diabetes and baseline cardiovascular disease risk on the treatment effect of intensive blood pressure lowering based on data and pooled analysis from two randomized trials (ACCORD-BP [Action to Control Cardiovascular Risk in Diabetes Blood Pressure]and SPRINT [Systolic Blood Pressure Intervention Trial] studies; total of 14,094 patients). The researchers found that the mean baseline systolic blood pressure was 139.5 mm Hg for the cohort and just over one-third (33.6 percent) had type 2 diabetes. The hazard ratio for the primary composite end point of unstable angina, myocardial infarction, acute heart failure, stroke, and cardiovascular death was 0.82 (P = 0.0017). There was a nonsignificant interaction between intensive blood pressure lowering and type 2 diabetes (P = 0.13). While the 10-year cardiovascular risk was higher in patients with type 2 diabetes, there was no interaction between the risk and treatment effect (P = 0.84).

For patients with acute coronary syndromes (ACS), diabetes mellitus (DM), but not pre-DM, is associated with an increased risk of major adverse cardiac events (MACE), according to a study published online Oct. 18 in the Journal of the American College of Cardiology. Serdar Farhan, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the impact of pre-DM on coronary plaque characteristics and ischemic outcome in patients with ACS. Participants underwent quantitative coronary angiography, grayscale intravascular ultrasound (IVUS), and radiofrequency IVUS after successful percutaneous coronary intervention. Patients were categorized based on their glucometabolic status as normal glucose metabolism (NGM; 162 patients), pre-DM (202 patients), and DM (183 patients). The researchers found that there were no significant between-group differences with respect to IVUS findings indicative of vulnerable plaques. Compared to patients with pre-DM or NGM, patients with DM had a higher crude rate of MACE (25.9 versus 16.3 and 16.1 percent; P = 0.03 and 0.02, respectively). Using NGM as the reference group, DM, but not pre-DM, was correlated with increased risk of MACE in an adjusted model (hazard ratios, 2.2 [95 percent confidence interval, 1.25 to 3.86; P = 0.006] and 1.29 [95 percent confidence interval, 0.71 to 2.33; P = 0.41]).

A new screening tool can adequately detect risk of diabetic retinopathy in adults with diabetes in low-income communities in Mexico, according to a study published in the October issue of Preventing Chronic Disease. Kenny Mendoza-Herrera, from the National Institute of Public Health in Mexico, and colleagues analyzed biochemical, clinical, anthropometric, and sociodemographic information from 1,000 adults with diabetes in low-income communities in Mexico in order to develop a screening tool based on a predictive model for early detection of diabetic retinopathy. Time since diabetes diagnosis, high blood glucose levels, systolic hypertension, and physical inactivity were risk factors included in the screening tool. The researchers found that the model had a mean area under the receiver operating characteristic curve (AUC ROC) of 0.78 in the validation data set. Using the optimized cut point that best represented the study population, the model had a sensitivity of 82.9 percent and a specificity of 61.9 percent. "We developed a low-cost and easy-to-apply screening tool to detect people at high risk of diabetic retinopathy in Mexico," the authors write. "Although classification performance of our tool was acceptable (AUC ROC > 0.75), error rates (precision) depend on false-negative and false-positive rates. Therefore, confirmatory assessment of all cases in mandatory."

Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma (HCC), according to a study scheduled for presentation at The Liver Meeting, held by the American Association for the Study of Liver Diseases from Oct. 20 to 24 in Washington, D.C. Teng-Yu Lee, M.D., Ph.D., from Taichung Veterans General Hospital in Taiwan, and colleagues used data from Taiwan's National Health Insurance Research Database from 1998 to 2012. Patients with non-hepatitis B infections were excluded, as were those with HCC before the follow-up index dates. A total of 1,553 patients who continuously received daily aspirin ≥90 days were randomly matched (1-to-4 ratio) with 6,212 patients who never received anti-platelet therapy based on baseline characteristics, the index date, and nucelos(t)ide analogue (NA) use during follow-up. The researchers found that the cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group in five years (2.86 percent versus 5.59 percent). Aspirin therapy was independently associated with a reduced HCC risk (hazard ratio [HR], 0.63) in a multivariable regression analysis. An increased HCC risk was independently associated with older age (HR, 1.03 per year), male gender (HR, 2.65), cirrhosis (HR, 1.89), and diabetes mellitus (HR, 1.51). NA (HR, 0.57) and statin (HR, 0.57) use were associated with a decreased HCC risk.